Clinical trials: Hypercytokinemia
Mesenchymal Stromal Cells, Remestemcel-L
MSCs in COVID-19 ARDS
The mortality rate in SARS-CoV-2-related severe ARDS is high despite treatment with antivirals, glucocorticoids, immunoglobulins, and ventilation.
- Conditions
- Mesenchymal Stromal Cells, Remestemcel-L, Acute Respiratory Distress Syndrome, COVID
- Trial name
- NCT04371393
- Testing
- Remestemcel-L
- Where
- 21 sites in United States
- Volunteers
- 223 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Sepsis, Septic Shock
Influence of Cytosorb on Amount of Catecholamine and Mortality in Sepsis
The aim of this retrospective study was to identify if the enrolled patient might have had a profit of Cytosorb therapy. Primarily the decline in catecholamine therapy under Cytosorb therapy will be investigated.
- Conditions
- Sepsis, Septic Shock, Cytokine Storm, Cytokine Release Syndrome
- Trial name
- NCT04567199
- Testing
- Observational, retrospective
- Where
- Austria
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Medical University Innsbruck
DLBCL, Multiple Myeloma
Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy
Recently chimeric antigen receptor (CAR) T-cell therapy, a new class of chemo therapy, has gained regulatory approval for the treatment of diseases such as B-cell lymphoma.
- Conditions
- DLBCL, Multiple Myeloma, Cytokine Release Syndrome, Myocarditis
- Trial name
- NCT05414162
- Testing
- Cardiac MRI
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- University Hospital, Bonn
Covid19 Pneumonia
The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation
Title: The use of Tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation.
- Trial name
- NCT04377750
- Testing
- Tocilizumab
- Where
- 4 sites in Israel
- Volunteers
- 500 people
- Sponsor
- Hadassah Medical Organization
Lymphoma, B-Cell, Neurotoxicity
Magnetic Resonance Imaging in Immune Effector Cell-Associated Neurotoxicity Syndrome
The treatment of large-cell B-cell lymphomas refractory to more than 2 lines of therapy has recently been revolutionized by the use of immunotherapies consisting of autologous genetically modified cells or CAR-T CELLS (chimeric…
- Trial name
- MR-ICANS (NCT05510596)
- Testing
- Magnetic Resonance Imaging with contrast injection, Blood withdrawal, Neuropsychological tests
- Where
- France
- Volunteers
- 25 people
- Sponsor
- University Hospital, Montpellier
Sepsis, Lymphocyte Disorder T
Esmolol in Sepsis Management:Evaluating Immunomodulatory Effects and Impact on Patient Outcomes
Evaluate the effectiveness of esmolol, a selective β1-adrenergic receptor blocker, in modulating immune responses and improving patient outcomes in sepsis.
- Conditions
- Sepsis, Lymphocyte Disorder T, Immunologic Paralysis, Catecholamine; Overproduction
- Trial name
- NCT06390748
- Testing
- esmolol
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Lin Chen
Sars-CoV2
Rhu-pGSN for Severe Covid-19 Pneumonia
Study Objectives: Primary To assess the efficacy (survival without organ failure on Day 14) of three doses of rhu-pGSN administered intravenously (IV) plus standard of care (SOC) to hospitalized subjects with a primary diagnosis…
- Trial name
- NCT04358406
- Testing
- Recombinant human plasma gelsolin (Rhu-pGSN)
- Where
- 3 sites in Romania, Spain
- Volunteers
- 64 people
- Sponsor
- BioAegis Therapeutics Inc.
Cytokine Release Syndrome in COVID-19-induced Pneumonia
Canakinumab MAP in COVID-19 Pneumonia With CRS
This is a global Managed Access Program (MAP) to provide access to canakinumab to patients with cytokine release syndrome resulting from COVID-19 pneumonia
- Trial name
- NCT04476706
- Testing
- canakinumab
- Sponsor
- Novartis Pharmaceuticals
Covid19
Vitamin D, Omega-3, and Combination Vitamins B, C and Zinc Supplementation for the Treatment and Prevention of COVID-19
The NUTROVID Factorial Trials The purpose of the NUTROVID-Prevent and NUTROVID-Treat Factorial Trials is to determine whether Vitamin B Complex, Vitamin C, and Zinc; Vitamin D; and Omega3, taken at dosages approximating…
- Trial name
- NUTROVID (NCT04828538)
- Testing
- Vitamin D, Omega DHA / EPA, Vitamin C, Vitamin B complex and Zinc Acetate
- Where
- Mexico
- Volunteers
- healthy volunteers welcome
- Sponsor
- Hospital de la Soledad
Cytokine Storm
Interleukin-34 in Stage I and II Periodontitis
Interleukin 34 (IL-34) is the second active component of (colony-stimulating factor receptor) CSF-1R. With regards to periodontal disease, It is debatable whether IL-34 is a pro-inflammatory cytokine (as seen in rheumatic…
- Trial name
- NCT06052774
- Testing
- Non-Surgical periodontal therapy
- Where
- Egypt
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Cytokine Release Syndrome
Study of CTO1681 for the Prevention and Treatment of CRS in Patients Receiving CAR T-Cell Therapy
This is an interventional study to evaluate the use of CTO1681 in preventing or reducing CAR T-cell-induced toxicities like cytokine release syndrome (CRS).
- Trial name
- NCT05905328
- Testing
- CTO1681 10 µg, CTO1681 20 μg, CTO1681 30 μg
- Where
- 6 sites in United States
- Volunteers
- 54 people
- Sponsor
- CytoAgents, Inc.
Cytokine Release Syndrome, ICANS
Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy
This study will evaluate the use of siltuximab to decrease the severity of cytokine release syndrome (CRS) and immune effector cell-associated neurological syndrome (ICANS) in patients who will receive chimeric antigen receptor…
- Conditions
- Cytokine Release Syndrome, ICANS, Lymphoma, Non-Hodgkin, Multiple Myeloma
- Trial name
- NCT04975555
- Testing
- Siltuximab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Alabama at Birmingham
COVID-19
Plasma Exchange in Covid-19 Patients With Anti-interferon Autoantibodies
COVID-19 associated mortality remains high despite the advances in therapeutics such as dexamethasone. The severity of COVID-19 results from direct viral cytotoxicity, and the inflammatory response, which is associated with a…
- Trial name
- EPIC (NCT05182515)
- Testing
- Therapeutic plasma exchange
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Centre Hospitalier St Anne
COVID-19
Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib in the treatment of participants with COVID-19-associated Acute Respiratory Distress Syndrome (ARDS) who require mechanical ventilation.
- Trial name
- NCT04377620
- Testing
- Ruxolitinib
- Where
- 36 sites in United States, Russia
- Volunteers
- 211 people
- Sponsor
- Incyte Corporation
Covid19, Cytokine Release Syndrome
Investigational Treatments for COVID-19 in Tertiary Care Hospital of Pakistan
Beyond supportive care, there are currently no proven treatment options for coronavirus disease (COVID-19) and related pneumonia, caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).Investigators have seen…
- Conditions
- Covid19, Cytokine Release Syndrome, Critical Illness, ARDS
- Trial name
- NCT04492501
- Testing
- Therapeutic Plasma exchange, Convalescent Plasma, Tocilizumab
- Where
- Pakistan
- Volunteers
- 600 people
- Sponsor
- UNICEF
Hemophagocytic Lymphohistiocytosis
Tocilizumab and Hemophagocytic Lymphohistiocytosis (HLH)
This study seeks to determine the efficacy of tocilizumab (TCZ) in patients with hemophagocytic lymphohistiocytosis (HLH) and high cytokine levels (proteins involved in inflammation) in an attempt to decrease the damage caused by…
- Trial name
- NCT02007239
- Testing
- tocilizumab
- Where
- United States
- Sponsor
- Children's Hospital of Philadelphia
Multiple Myeloma, Cytokine Release Syndrome
Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM
The purpose of this study is to examine the safety, efficacy and feasibility of the use of one standard dose of siltuximab prior to teclistamab infusion.
- Conditions
- Multiple Myeloma, Cytokine Release Syndrome, Refractory Multiple Myeloma, Immune Effector Cell Associated Neurotoxicity Syndrome
- Trial name
- NCT06352866
- Testing
- Siltuximab, Teclistamab(FDA-approved)
- Where
- United States
- Sponsor
- Jack Khouri, MD
Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL), Relapsed/Refractory Non-Hodgkin Lymphoma
NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)
The NexCAR19 study is a national, open-label, multicenter Phase 2-3 clinical trial designed to evaluate the efficacy and safety of the anti-CD19 chimeric antigen receptor (CAR) T-cell product, Talikabtagene Autoleucel, in…
- Conditions
- Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL), Relapsed/Refractory Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), High-grade B-cell Lymphoma (HGBCL)
- Trial name
- NexCAR19 (NCT07502118)
- Testing
- Talikabtagene Autoleucel
- Where
- 4 sites in Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Health Institutes of Turkey
Cytokine Release Syndrome
Safety and Tolerability Study of IV ST266 in COVID-19 Subjects
The primary aim of the study is to evaluate the safety and tolerability of open-label ST266 given to subjects with confirmed COVID-19 infection through IV administration once a day of 5 consecutive days.
- Trial name
- NCT04720378
- Testing
- ST266
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Noveome Biotherapeutics, formerly Stemnion
Coronavirus Disease 2019 (COVID-19) Pneumonia
Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19
The primary objective of this study is to assess whether the use of lenzilumab in addition to current standard of care can alleviate the immune-mediated cytokine release syndrome (CRS) and improve ventilator-free survival in…
- Trial name
- NCT04351152
- Testing
- Lenzilumab, Standard of Care
- Where
- 29 sites in United States, Brazil
- Volunteers
- 520 people
- Sponsor
- Humanigen, Inc.